Cipla Ltd. News and Updates

Name: Latest research reports of Cipla Ltd. authored by Geojit BNP Paribas and published by - Trendlyne research reports.
Item: Cipla Ltd.
Rating: 5
Author: Geojit BNP Paribas

Keep track of all breaking news on Cipla Ltd. from all sources in a single place.

Load latest

Cipla Ltd.

17 Dec 2024

1470.20

0.31%

Cipla shares rise over 2% as Kotak forecasts better days ahead, upgrades rating to buy'

Economic Times

Cipla shares rose by 2.4% to Rs 1,483.40 on Tuesday after Kotak Institutional Equities upgraded the stock from "add" to "buy," with a target price of Rs 1,725. This suggests a potential upside of over 16% from the current levels.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla shares gain; Kotak upgrades stock to 'Buy' from 'Add'; check target

Business Standard | 17 Dec 2024

Cipla Ltd.

12 Dec 2024

1470.20

0.31%

Cipla's inhaled insulin' from US' MannKind Corp adds a layer of convenience' for those with diabetes

Business Line

Recently, India's Central Drugs Standard Control Organisation gave Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder in India

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

HSBC bullish on Indian pharma stocks for 2025

Economic Times | 12 Dec 2024 1 more

Cipla Ltd.

11 Dec 2024

1470.20

0.31%

Cipla to bring in inhaled insulin Afreeza from US' MannKind Corporation

Business Line

The Central Drugs Standard Control Organisation (CDSCO) has given Cipla the approval to exclusively distribute and market Afrezza (human insulin) inhalation powder, in India

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla gets approval to market Afrezza insulin inhalation powder in India

Business Standard | 11 Dec 2024

Cipla Ltd.

04 Dec 2024

1470.20

0.31%

CIPLA LTD

Buy: Cipla Ltd.

Target

Geojit BNP Paribas

Cipla Ltd. is trading below all available SMAs

Cipla Ltd.

02 Dec 2024, 05:42PM

1470.20

0.31%

Cipla Promoters Sell 1.72% Stake For Over Rs 2,000 Crore

NDTV Profit

The promoter group held a 31.66% stake in the Mumbai-headquartered company before the sale of equity, while after it, their cumulative holding was reduced to 29.94%.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Cipla receives unsolicited ESG rating of B+ from SES Research

Business Line | 02 Dec 2024, 11:23AM 1 more

Cipla Ltd.

29 Nov 2024

1470.20

0.31%

Cipla promoters may sell 1.72% stake worth Rs 2,000 crore via block deal

Business Standard

The floor price for the Cipla share sale has been set at Rs 1,442 per share, reflecting a 6 per cent discount to the current market price

Cipla Ltd. is trading below all available SMAs

Cipla promoters to sell 1.72% stake in likely block deal worth Rs 2,000 crore: Report

Economic Times | 29 Nov 2024 1 more

Cipla Ltd.

28 Nov 2024

1470.20

0.31%

CIPLA LTD.

Buy: Cipla Ltd.

Recommendation Target

Prabhudas Lilladhar

Prabhudas Lilladhar released a Buy report for Cipla Ltd. with a price target of 1730.0 on 14 May, 2025.

Cipla Ltd.

13 Nov 2024

1470.20

0.31%

Drug maker Cipla gets 8 observations from USFDA for Bengaluru facility

Business Standard

Drug maker Cipla on Wednesday said the US health regulator has issued eight observations after inspecting its Bengaluru-based plant. The US Food and Drugs Administration (USFDA) conducted an inspection at the company's manufacturing facility in Virgonagar, Bengaluru from November 7- 13, the Mumbai-based based drug maker said in a filing to BSE. On conclusion of the inspection, the company received eight observations in Form 483, it added. The company said it will work closely with the USFDA and remain committed to addressing these observations comprehensively within stipulated time.

Number of FII/FPI investors increased from 1077 to 1114 in Mar 2025 qtr.

Cipla Gets Eight Observations After FDA Inspection

NDTV Profit | 13 Nov 2024

Cipla Ltd.

05 Nov 2024

1470.20

0.31%

Cipla eyes rebound in One India' business despite slow seasonal growth

Business Line

Despite facing supply issues with its generic Lanreotide in the US, Cipla anticipates a recovery in sales starting from Q4 FY25.

Prabhudas Lilladhar released a Buy report for Cipla Ltd. with a price target of 1730.0 on 14 May, 2025.

Cipla Ltd.

04 Nov 2024

1470.20

0.31%

Cipla Share Price Rises 11% In Three Sessions As Brokerages Positive On US FDA Clearance

NDTV Profit

Cipla share price had fallen after the company's September quarter results as analysts cut their target price, citing weaker than expected domestic business and challenges in its key products.

Cipla Ltd. has an average target of 1699.67 from 9 brokers.

Is Cipla Ltd. worth buying?

605 Votes:

Buy 76.03%

Sell 14.05%

Hold 9.92%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf